KF-26777
 | |
| Systematic (IUPAC) name | |
|---|---|
| (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one | |
| Clinical data | |
| Identifiers | |
| Synonyms | KF-26777 |
| Chemical data | |
| Formula | C16H18BrN5O |
| 376.250 g/mol | |
|
SMILES
| |
 (what is this?) (verify) | |
KF-26777 is a drug which acts as a potent and selective antagonist for the adenosine A3 receptor, with sub-nanomolar affinity (A3 Ki=0.2nM) and high selectivity over the other three adenosine receptor subtypes.[1] Simple xanthine derivatives such as caffeine and DPCPX have generally low affinity for the A3 subtype and must be extended by expanding the ring system and adding an aromatic group to give high A3 affinity and selectivity.[2]
References
- ↑ Saki M, Tsumuki H, Nonaka H, Shimada J, Ichimura M (May 2002). "KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist". European Journal of Pharmacology 444 (3): 133–41. doi:10.1016/S0014-2999(02)01662-X. PMID 12063073.
- ↑ Baraldi PG, Tabrizi MA, Gessi S, Borea PA (January 2008). "Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility". Chemical Reviews 108 (1): 238–63. doi:10.1021/cr0682195. PMID 18181659.